EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer

Elena Shagisultanova, Hannah Parris, Long Liu, Stephanie Giangiuli, Dexiang Gao, Jennifer R Diamond, Radhika Acharya-Leon, Peter Kabos, Virginia F Borges

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2025.06.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Elena Shagisultanova und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO; Young Women's Breast Cancer Translational Program, Universi…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Center for Advancing Translational Sciences, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: HER2-targeted tyrosine kinase inhibitors (TKIs) tucatinib, lapatinib and neratinib are standard agents for treatments of HER2-positive (HER2+) metastatic breast cancer. Due to their penetration through the blood-brain barrier, these agents are especially beneficial for patients with brain metastases. To date, limited data exists on the sequential use of different HER2-targeted TKIs, and it is unknown if reusing the same TKI as a part of different treatment regimens provides clinical benefits. METHODS: We performed a retrospective single institution study (IRB 23-2337) and identified N = 105 patients with HER2+ metastatic breast cancer and a TKI regimen of at least 1 month. We then performed a manual abstraction to identify patients who had at least 2 TKI regimens (N = 24) and estimated time on treatment (median and range in months). Best responses to TKI treatments were evaluated by MD review. Patients were censored at the time of the last follow up when the end of treatment data were not available. RESULTS: In our patient cohort, 14 of 24 patients (58%) stayed on the second or third TKI regimen for greater than 6 months, and 10 of 24 patients (42%) were on the subsequent TKI regimen(s) for longer than the first one. Time on a non-TKI regimen between the first and second TKI was not associated with the duration of benefit from the second TKI. CONCLUSION: Our data support using different HER2-targeted TKI regimens in sequence, offering additional effective treatment options for patients with HER2+ metastatic breast cancer, including patients with brain metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAdultAgedLapatinibQuinolinesAged, 80 and overTreatment OutcomeFollow-Up StudiesPyridinesOxazolesTyrosine Kinase InhibitorsQuinazolines

Stichwörter der Autor:innen

Brain metastasesHER2-positive breast cancerLapatinibNeratinibTucatinib

Substanzen

Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsLapatinibQuinolinesPyridinesOxazolesTyrosine Kinase InhibitorsQuinazolinesERBB2 protein, humanneratinib

Autor:innen und Institutionen

  • Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO; Diane O'Connor Thompson Brea…
  • Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO; Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO.
  • Young Women's Breast Cancer Translational Program, University of Colorado Cancer Center, Aurora, CO.
  • Diane O'Connor Thompson Breast Center, University of Colorado Hospital, UCHealth, Aurora, CO.
  • Department of Pediatrics, Children's Hospital of Colorado, Aurora, CO; Bioinformatics and Biostatistics Shared Resource, University of Colorado Cancer Center, Aurora, CO.
  • Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO; Diane O'Connor Thompson Breast Center, University of Colorado Hospital, UCHealth, Aurora, CO.

Förderung

  • NCI NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health
  • American Association for Cancer Research
  • Cancer Center, University of Colorado
  • Breast Cancer Research Foundation
  • David F. and Margaret T. Grohne Family Foundation

Zitieren

APA

Shagisultanova, E., Parris, H., Liu, L., Giangiuli, S., Gao, D., Diamond, J. R., Acharya-Leon, R., Kabos, P., & Borges, V. F. (2025). Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.06.004

Vancouver

Shagisultanova E, Parris H, Liu L, Giangiuli S, Gao D, Diamond JR, et al. Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.06.004

BibTeX
@article{Shagisultanova2025,
  author = {Shagisultanova, Elena and Parris, Hannah and Liu, Long and Giangiuli, Stephanie and Gao, Dexiang and Diamond, Jennifer R and Acharya-Leon, Radhika and Kabos, Peter and Borges, Virginia F},
  title = {Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2025.06.004}
}
Kostenlos starten →